Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational study
R Venegas-Rodriguez, María del Carmen Domínguez-Horta(Centro de Ingeniería Genética y Biotecnología), Inti Grecesqui-Cruz(Hospital Oncológico Docente "Conrado Benítez García"), Leticia del Rosario-Cruz(Hospital Militar Central), Aliusha Rittoles Navarro(Hospital Oncológico Docente "Conrado Benítez García"), Gerardo Guillén(Hunan City University), R Santana-Sanchez, Anabel Serrano-Díaz(Centro de Ingeniería Genética y Biotecnología), Mabel Hernández-Cedeño(Centro de Ingeniería Genética y Biotecnología), Ruben Peña-Ruiz, Anadys Segura-Fernández(Hospital Oncológico Docente "Conrado Benítez García"), G. Martínez-Donato(Centro de Ingeniería Genética y Biotecnología), Liam Pérez-Aguilera(Hospital Oncológico Docente "Conrado Benítez García")
Cited by 7
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134